ARVELLE THERAPEUTICS

arvelle-therapeutics-logo

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.

#SimilarOrganizations #People #Financial #Website #More

ARVELLE THERAPEUTICS

Social Links:

Industry:
Biotechnology

Founded:
2019-01-01

Address:
Basel, Basel-Stadt, Switzerland

Country:
Switzerland

Website Url:
http://www.arvelletx.com

Total Employee:
1+

Status:
Active

Contact:
(888) 317-1041

Email Addresses:
[email protected]

Total Funding:
221.85 M USD

Technology used in webpage:
Euro Google Font API Font Awesome Nginx GStatic Google Static Content


Similar Organizations

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

carbonworks-logo

CarbonWorks

CarbonWorks is specialising in the use of microalgae to capture and utilise carbon dioxide.

colorifix-logo

Colorifix

Colorifix is the first company to use a biological process to produce, deposit and fix pigments onto textiles.

cytokinetics-logo

Cytokinetics

Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

inbrain-neuroelectronics-logo

INBRAIN Neuroelectronics

INBRAIN Neuroelectronics is a bioelectronics company using graphene to build the least invasive and most intelligent neural platform

lightcast-discovery-logo

Lightcast Discovery

Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.

micropep-technologies-logo

Micropep Technologies

Micropep Technologies is a biotech company that focused on biological alternatives to agrochemicals.

piqur-therapeutics-logo

PIQUR Therapeutics

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.

reata-pharmaceuticals-logo

Reata Pharmaceuticals

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.

Founder


gregory-weinhoff_image

Gregory Weinhoff

ilise-lombardo_image

Ilise Lombardo

mark-altmeyer_image

Mark Altmeyer

Investors List

kbinvest_image

KB Investment

KB Investment investment in Series A - Arvelle Therapeutics

h-i-g-biohealth-partners_image

H.I.G. BioHealth Partners

H.I.G. BioHealth Partners investment in Series A - Arvelle Therapeutics

bpv-capital-management_image

BPV Capital Management

BPV Capital Management investment in Series A - Arvelle Therapeutics

life-sciences-partners_image

EQT Life Sciences

EQT Life Sciences investment in Series A - Arvelle Therapeutics

edmond-de-rothschild-investment-partners_image

Andera Partners

Andera Partners investment in Series A - Arvelle Therapeutics

f-prime-capital-partners_image

F-Prime Capital

F-Prime Capital investment in Series A - Arvelle Therapeutics

novaquest-capital-management_image

Novaquest Capital Management

Novaquest Capital Management investment in Series A - Arvelle Therapeutics

bpv-capital-management_image

BPV Capital Management

BPV Capital Management investment in Series A - Arvelle Therapeutics

novaquest-capital-management_image

Novaquest Capital Management

Novaquest Capital Management investment in Series A - Arvelle Therapeutics

h-i-g-biohealth-partners_image

H.I.G. BioHealth Partners

H.I.G. BioHealth Partners investment in Series A - Arvelle Therapeutics

Official Site Inspections

http://www.arvelletx.com

  • Host name: 208.91.197.27
  • IP address: 208.91.197.27
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Arvelle Therapeutics"

Arvelle Therapeutics - Crunchbase Company Profile & Funding

Organization. Arvelle Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Arvelle Therapeutics is a โ€ฆSee details»

Angelini Pharma today finalized the acquisition agreement of โ€ฆ

Feb 2, 2021 Juan Vergez - Head of Marketing and Corporate Communications - Email: [email protected]. SK Biopharmaceuticals. Hyongki Park - Head of โ€ฆSee details»

Angelini Pharma acquires Arvelle Therapeutics

Jan 4, 2021 Juan Vergez - Head of Marketing and Corporate Communications - [email protected] Consilium Strategic: Communications (international strategic โ€ฆSee details»

Arvelle Therapeutics - EQT Group

Nov 26, 2024 Latest news. 02 December 2024 EQT and GIC to acquire majority stake in Calisen, a leading independent smart metering company in the UK; 29 November 2024See details»

Angelini Pharma acquires Arvelle Therapeutics to create a leading ...

Jan 4, 2021 They have worked in close collaboration with the European regulators to advance the marketing authorization application (MAA), and they have successfully prepared for launch โ€ฆSee details»

Angelini Pharma acquires Arvelle Therapeutics

Angelini Pharma announced today the acquisition of Arvelle Therapeutics, the Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering โ€ฆSee details»

Arvelle Therapeutics Inc. - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Arvelle Therapeutics Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»

Angelini Pharma acquires Arvelle Therapeutics to create a leading ...

ROME, Jan. 14, 2021 /PRNewswire/ -- Angelini Pharma, an international pharmaceutical company which is a part of the private Italian Angelini Group โ€“ and Arvelle Therapeutics, a โ€ฆSee details»

Arvelle Therapeutics - Overview, News & Similar companies

Jan 5, 2021 www.arvelletx.com. Revenue $19.7 Million. Industry Pharmaceuticals Healthcare . Recent News & Media. Angelini Pharma acquires Arvelle Therapeutics to create a le... Jan 14, โ€ฆSee details»

Arvelle Therapeutics - Company Profile - Tracxn

Aug 17, 2021 Arvelle Therapeutics - Developer of small molecules for the treatment of partial-onset seizures. Acquired by Angelini Pharma. Raised a total funding of $223M over 2 rounds โ€ฆSee details»

Arvelle Therapeutics - Craft

Arvelle Therapeutics is a biopharmaceutical company. The company licenced the anti-epileptic candidate cenobamate (YKP3089). Cenobamate is used for the treatment of adults with focal โ€ฆSee details»

Arvelleโ€™s Competitors, Revenue, Number of Employees, Funding

Arvelleโ€™s Profile, Revenue and Employees. Arvelle is a biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of central nervous system disorders. โ€ฆSee details»

Arvelle Therapeutics - PitchBook

Arvelle Therapeutics General Information Description. Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorders.See details»

Arvelle Therapeutics Company Profile -Sales, Contacts, โ€ฆ

Arvelle Therapeutics is in the Pharmaceutical Preparations industry within the Chemicals and Allied Products sector and has been in business for approximately 5 years.See details»

About Us | Arvelle Therapeutics

[email protected]. Regus Oxford Street (Oxford Circus) 33 Cavendish Square, London, Greater London W1G 0PW United Kingdom. UK11420P | April 2022 +44 (20) 81247407. โ€ฆSee details»

Arvelle Therapeutics GmbH (aquired by Angelini Pharma)

Arvelle Therapeutics GmbH (aquired by Angelini Pharma): Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients โ€ฆSee details»

Arvelle Therapeutics | H.I.G. BioHealth Partners

Arvelle Therapeutics is a biopharmaceutical company bringing innovative solutions to patients suffering from CNS disorders. Arvelle Therapeutics is a biopharmaceutical company with the โ€ฆSee details»

Arvelle Therapeutics (Switzerland) Funding: $221.8M

Nov 23, 2024 Arvelle carries forward the European rights to cenobamate, an anti-epileptic drug for partial-onset...See details»

NovaQuest Capital Enters Into Financing Agreement With Arvelle ...

BASEL, Switzerlandโ€“(BUSINESS WIRE)โ€“SK Biopharmaceuticals and Arvelle Therapeutics GmbH today announced that they have entered into an exclusive licensing agreement for โ€ฆSee details»

ONTOZRYโ„ข (cenobamate) receives positive CHMP opinion for the โ€ฆ

Jan 29, 2021 Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate When approved, cenobamate will provide new hope in helping adult patients with โ€ฆSee details»

linkstock.net © 2022. All rights reserved